Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) | MicrobiomeTrials← Back to trialsNCT07209462
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-11-22Est. Completion: 2027-10
Enrollment target: 60 participants Locations- Southwest Autism Research & Resource Center, Phoenix, Arizona, United States
- Amnova Clinical Research, LLC, Irvine, California, United States
- Children's Hospital of Orange County - Pediatric Subspecialty, Orange, California, United States
- Uc Davis Mind Institute, Sacramento, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Neurology, Miami, Florida, United States
- Emory University - The Emory Clinic - Clifton Road, Atlanta, Georgia, United States
- Rush University Medical Center-Clinical Operation, Chicago, Illinois, United States
- Kennedy Krieger Institute, John Hopkins School of Medicine, Baltimore, Maryland, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- UMass Memorial Health, Worcester, Massachusetts, United States
- University of Minnesota Department of Medicine, Minneapolis, Minnesota, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Suburban Research Associates, Media, Pennsylvania, United States
- Intermountain Healthcare - Park City Specialty Clinic, Salt Lake City, Utah, United States
Other microbiome trials you might be interested in
Neurodevelopmental DisordersAutismAutism Spectrum DisorderFragile X SyndromeTuberous Sclerosis22Q11 Deletion Syndrome22Q11 DeletionADHDTic DisordersTourette SyndromeTourette Syndrome in ChildrenTourette Syndrome in AdolescenceADHD - Combined TypeADHD Predominantly Inattentive TypeADHD, Predominantly Hyperactive - ImpulsiveAnxietyAnxiety Disorders
There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental d…
Calgary, CanadaEst. completion Sep 2027
Fragile X Syndrome (FXS)Fragile X Syndrome
The purpose of this Phase IIa study is to evaluate the safety, tolerability, and effectiveness of CTH120 in adult males …
Barcelona, SpainEst. completion May 2027